Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network.

Moreau P, Sonneveld P, Boccadoro M, Cook G, Mateos MV, Nahi H, Goldschmidt H, Dimopoulos MA, Lucio P, Bladé J, Delforge M, Hajek R, Ludwig H, Facon T, Miguel JFS, Einsele H.

Haematologica. 2019 Dec;104(12):2358-2360. doi: 10.3324/haematol.2019.224204. Epub 2019 Aug 22.

2.

Correction: Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role.

Rodríguez-Otero P, Mateos MV, Martínez-López J, Martín-Calvo N, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Bargay J, Bengoechea E, González Y, de Oteyza JP, Gironella M, Encinas C, Martín J, Cabrera C, Palomera L, de Arriba F, Cedena MT, Paiva B, Puig N, Oriol A, Bladé J, Lahuerta JJ, Miguel JFS.

Leukemia. 2019 Apr;33(4):1056. doi: 10.1038/s41375-019-0408-x.

PMID:
30846864
3.

Clarification of the definition of complete response in multiple myeloma.

Durie BG, Miguel JF, Blade J, Rajkumar SV.

Leukemia. 2015 Dec;29(12):2416-7. doi: 10.1038/leu.2015.290. Epub 2015 Oct 21. No abstract available.

PMID:
26487274
4.

Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers.

Agirre X, Castellano G, Pascual M, Heath S, Kulis M, Segura V, Bergmann A, Esteve A, Merkel A, Raineri E, Agueda L, Blanc J, Richardson D, Clarke L, Datta A, Russiñol N, Queirós AC, Beekman R, Rodríguez-Madoz JR, San José-Enériz E, Fang F, Gutiérrez NC, García-Verdugo JM, Robson MI, Schirmer EC, Guruceaga E, Martens JH, Gut M, Calasanz MJ, Flicek P, Siebert R, Campo E, Miguel JF, Melnick A, Stunnenberg HG, Gut IG, Prosper F, Martín-Subero JI.

Genome Res. 2015 Apr;25(4):478-87. doi: 10.1101/gr.180240.114. Epub 2015 Feb 2.

5.

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF.

Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26. Review.

6.

NADPH oxidases as therapeutic targets in chronic myelogenous leukemia.

Sánchez-Sánchez B, Gutiérrez-Herrero S, López-Ruano G, Prieto-Bermejo R, Romo-González M, Llanillo M, Pandiella A, Guerrero C, Miguel JF, Sánchez-Guijo F, Del Cañizo C, Hernández-Hernández A.

Clin Cancer Res. 2014 Aug 1;20(15):4014-25. doi: 10.1158/1078-0432.CCR-13-3044. Epub 2014 May 15.

7.

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma.

Dimopoulos MA, Leleu X, Palumbo A, Moreau P, Delforge M, Cavo M, Ludwig H, Morgan GJ, Davies FE, Sonneveld P, Schey SA, Zweegman S, Hansson M, Weisel K, Mateos MV, Facon T, Miguel JF.

Leukemia. 2014 Aug;28(8):1573-85. doi: 10.1038/leu.2014.60. Epub 2014 Feb 5. Review.

8.

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG).

Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, Kumar S, Usmani S, Roodman D, Niesvizky R, Einsele H, Anderson KC, Dimopoulos MA, Avet-Loiseau H, Mellqvist UH, Turesson I, Merlini G, Schots R, McCarthy P, Bergsagel L, Chim CS, Lahuerta JJ, Shah J, Reiman A, Mikhael J, Zweegman S, Lonial S, Comenzo R, Chng WJ, Moreau P, Sonneveld P, Ludwig H, Durie BG, Miguel JF.

Leukemia. 2014 Mar;28(3):525-42. doi: 10.1038/leu.2013.350. Epub 2013 Nov 20. Review.

9.

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.

Puig N, Sarasquete ME, Balanzategui A, Martínez J, Paiva B, García H, Fumero S, Jiménez C, Alcoceba M, Chillón MC, Sebastián E, Marín L, Montalbán MA, Mateos MV, Oriol A, Palomera L, de la Rubia J, Vidriales MB, Bladé J, Lahuerta JJ, González M, Miguel JF, García-Sanz R.

Leukemia. 2014 Feb;28(2):391-7. doi: 10.1038/leu.2013.217. Epub 2013 Jul 17.

PMID:
23860448
10.

Induction therapy for newly diagnosed multiple myeloma.

Lonial S, Miguel JF.

J Natl Compr Canc Netw. 2013 Jan 1;11(1):19-28. Review.

PMID:
23307978
11.

Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients.

Paiva B, Gutiérrez NC, Chen X, Vídriales MB, Montalbán MÁ, Rosiñol L, Oriol A, Martínez-López J, Mateos MV, López-Corral L, Díaz-Rodríguez E, Pérez JJ, Fernández-Redondo E, de Arriba F, Palomera L, Bengoechea E, Terol MJ, de Paz R, Martin A, Hernández J, Orfao A, Lahuerta JJ, Bladé J, Pandiella A, Miguel JF; GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative.

Leukemia. 2012 Aug;26(8):1862-9. doi: 10.1038/leu.2012.42. Epub 2012 Feb 15.

PMID:
22333880
12.

Current challenges in the management of patients with relapsed/refractory multiple myeloma.

Miguel JF, Mateos MV.

Oncology (Williston Park). 2011 Nov 15;25 Suppl 2:10-8. Review.

13.

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.

Mateos MV, Oriol A, Martínez-López J, Gutiérrez N, Teruel AI, de Paz R, García-Laraña J, Bengoechea E, Martín A, Mediavilla JD, Palomera L, de Arriba F, González Y, Hernández JM, Sureda A, Bello JL, Bargay J, Peñalver FJ, Ribera JM, Martín-Mateos ML, García-Sanz R, Cibeira MT, Ramos ML, Vidriales MB, Paiva B, Montalbán MA, Lahuerta JJ, Bladé J, Miguel JF.

Lancet Oncol. 2010 Oct;11(10):934-41. doi: 10.1016/S1470-2045(10)70187-X. Epub 2010 Aug 23.

PMID:
20739218
14.

Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders.

Paiva B, Almeida J, Pérez-Andrés M, Mateo G, López A, Rasillo A, Vídriales MB, López-Berges MC, Miguel JF, Orfao A.

Cytometry B Clin Cytom. 2010 Jul;78(4):239-52. doi: 10.1002/cyto.b.20512. Review.

15.

Effects of imatinib mesylate on normal bone marrow cells from chronic myeloid leukemia patients in complete cytogenetic response.

Sanchez-Guijo FM, Hernandez JM, Lumbreras E, Morais P, Santamaría C, Garcia JL, Gutierrez NC, Miguel JF, Del Cañizo MC.

Leuk Res. 2009 Jan;33(1):170-3. doi: 10.1016/j.leukres.2008.07.014. Epub 2008 Aug 21.

PMID:
18722011
16.

TCRgammadelta+ large granular lymphocyte leukemias reflect the spectrum of normal antigen-selected TCRgammadelta+ T-cells.

Sandberg Y, Almeida J, Gonzalez M, Lima M, Bárcena P, Szczepañski T, van Gastel-Mol EJ, Wind H, Balanzategui A, van Dongen JJ, Miguel JF, Orfao A, Langerak AW.

Leukemia. 2006 Mar;20(3):505-13.

PMID:
16437145
17.

CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.

Suárez L, Vidriales MB, García-Laraña J, Sanz G, Moreno MJ, López A, Barrena S, Martínez R, Tormo M, Palomera L, Lavilla E, López-Berges MC, de Santiago M, de Equiza ME, Miguel JF, Orfao A.

Clin Cancer Res. 2004 Nov 15;10(22):7599-606.

18.

Quality of life assessment in patients undergoing reduced intensity conditioning allogeneic as compared to autologous transplantation: results of a prospective study.

Díez-Campelo M, Pérez-Simón JA, González-Porras JR, García-Cecilia JM, Salinero M, Caballero MD, Cañizo MC, Ocio EM, Miguel JF.

Bone Marrow Transplant. 2004 Oct;34(8):729-38.

PMID:
15354204
19.

Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study.

Martín A, Caballero MD, Pérez-Simón JA, López-Holgado N, Mateos MV, Cañizo MC, Miguel JF.

Bone Marrow Transplant. 2004 Oct;34(8):675-82.

PMID:
15334049
20.

FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor.

Chillón MC, Fernández C, García-Sanz R, Balanzategui A, Ramos F, Fernández-Calvo J, González M, Miguel JF.

Hematol J. 2004;5(3):239-46.

PMID:
15167911
21.

Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation.

Perez-Simon JA, Diez-Campelo M, Martino R, Sureda A, Caballero D, Canizo C, Brunet S, Altes A, Vazquez L, Sierra J, Miguel JF.

Blood. 2003 Aug 1;102(3):1108-13. Epub 2003 Mar 20.

PMID:
12649159
22.

Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases.

García-Sanz R, Montoto S, Torrequebrada A, de Coca AG, Petit J, Sureda A, Rodríguez-García JA, Massó P, Pérez-Aliaga A, Monteagudo MD, Navarro I, Moreno G, Toledo C, Alonso A, Besses C, Besalduch J, Jarque I, Salama P, Rivas JA, Navarro B, Bladé J, Miguel JF; Spanish Group for the Study of Waldenström Macroglobulinaemia and PETHEMA (Programme for the Study and Treatment of Haematological Malignancies).

Br J Haematol. 2001 Dec;115(3):575-82. Review.

PMID:
11736938
23.

Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics.

García-Sanz R, Orfão A, González M, Tabernero MD, Bladé J, Moro MJ, Fernández-Calvo J, Sanz MA, Pérez-Simón JA, Rasillo A, Miguel JF.

Blood. 1999 Feb 1;93(3):1032-7.

PMID:
9920853
24.

Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications.

Escribano L, Orfao A, Díaz-Agustin B, Villarrubia J, Cerveró C, López A, Marcos MA, Bellas C, Fernández-Cañadas S, Cuevas M, Sánchez A, Velasco JL, Navarro JL, Miguel JF.

Blood. 1998 Apr 15;91(8):2731-6.

PMID:
9531582
25.

Blast crisis of chronic granulocytic leukemia with mast cell and basophilic precursors.

Soler J, O'Brien M, de Castro JT, Miguel JF, Kearney L, Goldman JM, Catovsky D.

Am J Clin Pathol. 1985 Feb;83(2):254-9.

PMID:
3855596

Supplemental Content

Loading ...
Support Center